Last Posted: Nov 25, 2023
- Ibrutinib and venetoclax as primary therapy in symptomatic treatment naïve Waldenström macroglobulinemia.
Jorge J Castillo, et al. Blood 2023 0
- Clonal Relationship and Mutation Analysis in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Associated With Diffuse Large B-cell Lymphoma.
Madeleine R Berendsen, et al. HemaSphere 2023 0 (11) e976
- Clinical Implications of Genomic Profile in Waldenström Macroglobulinemia.
David F Moreno, et al. Hematology/oncology clinics of North America 2023 0
- Mutational Profile in 75 Patients With Anti-Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic Targets.
Francesca Castellani, et al. Neurology(R) neuroimmunology & neuroinflammation 2023 0 (4)
- [Clonotypic analysis of immunoglobulin heavy chain sequences among 44 patients with Waldenström macroglobulinemia].
Tang Jing, et al. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 2023 0 (3) 263-268
- Bone Involvement as a Primary Rare Manifestation of Waldenstrom Macroglobulinemia: A Case Report and Prevalence in a Nationwide Population-Based Cohort Study.
Bhatti Khazra, et al. Journal of hematology 2023 0 (6) 233-239
- Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors.
Aldea Mihaela, et al. JCO precision oncology 2023 0 e2200583
- Waldenström macroglobulinemia and non-IgM-type lymphoplasmacytic lymphoma are genetically similar.
Awata-Shiraiwa Maaya, et al. Acta haematologica 2023 0
- MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.
Abeykoon Jithma P, et al. American journal of hematology 2017 0 (2) 187-194
- Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
Paludo Jonas, et al. British journal of haematology 2017 0 (1) 98-105
- Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.
Treon Steven P, et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 0 (27) 2755-2761
- Impact of MYD88 mutation status on histological transformation of Waldenström Macroglobulinemia.
Zanwar Saurabh, et al. American journal of hematology 2019 0 (3) 274-281
- Characteristics of Waldenström Macroglobulinemia in Korean Patients According to Mutational Status of MYD88 and CXCR4: Analysis Using Ultra-Deep Sequencing.
Shin Dong Woo, et al. Clinical lymphoma, myeloma & leukemia 2019 0 (8) e496-e505
- Venetoclax in Previously Treated Waldenström Macroglobulinemia.
Castillo Jorge J, et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021 0 (1) 63-71
- Cytogenetic and molecular abnormalities in Waldenström's macroglobulinemia patients: Correlations and prognostic impact.
Krzisch Daphné, et al. American journal of hematology 2021 0 (12) 1569-1579
- Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia.
Abeykoon Jithma P, et al. American journal of hematology 2021 0 (8) 945-953
- Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells.
Trojani Alessandra, et al. Cancers 2021 0 (8)
- Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia.
Tomowiak Cécile, et al. Blood advances 2021 0 (9) 2438-2446
- Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significance.
Alexander J Ryu et al. Blood cancer journal 2023 13(1) 28
- Flow cytometry detection of CD138 expression continuum between monotypic B and plasma cells is associated with both high IgM peak levels and MYD88 mutation and contributes to diagnosis of Waldenström macroglobulinemia.
Gayet Mylene, et al. Cytometry. Part B, Clinical cytometry 2021 0 (1) 62-69
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Graves Disease
- Huntington Disease
- Myasthenia Gravis
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Oct 1, 2023
- Page last updated:Dec 02, 2023
- Content source: